CoChat
Sign Up
Cited by 97

The DOI matches its Crossref record.

Synergistic antitumor activity of camptothecin–doxorubicin combinations and their conjugates with hyaluronic acid

Camacho, Kathryn M., Kumar, Sunny, Menegatti, Stefano, Vogus, Douglas R., Anselmo, Aaron C., Mitragotri, Samir·2015·Journal of Controlled Release
DOI 10.1016/j.jconrel.2015.04.031PMC PMC4470752
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2015.04.031

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 65

  1. Devita, 1975, Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer, Cancer, 35, 98, 10.1002/1097-0142(197501)35:1<98::AID-CNCR2820350115>3.0.CO;2-B · DOI
  2. Frei, 1961, Studies of sequential and combination antimetabolite therapy in acute leukemia: 6-mercaptopurine and methotrexate, Blood, 18, 431, 10.1182/blood.V18.4.431.431 · DOI
  3. Garcia, 2005, Phase I clinical trial of topotecan and pegylated liposomal doxorubicin, Cancer Invest., 23, 665, 10.1080/07357900500359877 · DOI
  4. Goff, 2008, A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies, Am. J. Clin. Oncol., 31, 413, 10.1097/COC.0b013e318168ef2a · DOI
  5. Harada, 2014, A phase I/II trial of irinotecan plus amrubicin supported with G-CSF for extended small-cell lung cancer, Jpn. J. Clin. Oncol., 44, 127, 10.1093/jjco/hyt198 · DOI
  6. Hotta, 2005, Phase I study of irinotecan and amrubicin in patients with advanced non-small-cell lung cancer, Anticancer Res, 25, 2429
  7. Lau, 2008, Population-based phase I trial of irinotecan and epirubicin, Am. J. Clin. Oncol., 31, 226, 10.1097/COC.0b013e3181605440 · DOI
  8. Mirchandani, 2005, Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., 11, 5912, 10.1158/1078-0432.CCR-04-1240 · DOI
  9. Morgensztern, 2009, A phase I study of pegylated liposomal doxorubicin and irinotecan in patients with solid tumors, Chemotherapy, 55, 441, 10.1159/000264925 · DOI
  10. Nishimura, 2007, Phase II study of irinotecan plus doxorubicin for early recurrent or platinum-refractory ovarian cancer: interim analysis, Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc., 17, 159, 10.1111/j.1525-1438.2006.00728.x · DOI
  11. Nogami, 2012, Phase II study of irinotecan and amrubicin in patients with relapsed non-small cell lung cancer: Okayama Lung Cancer Study Group Trial 0402, Acta Oncol. (Stockholm, Sweden), 51, 768, 10.3109/0284186X.2011.648342 · DOI
  12. Oshita, 2008, Dose escalation study of amrubicin in combination with fixed-dose irinotecan in patients with extensive small-cell lung cancer, Oncology, 74, 7, 10.1159/000138350 · DOI
  13. Ryan, 2000, A phase I study of liposomal doxorubicin (Doxil) with topotecan, Am. J. Clin. Oncol., 23, 297, 10.1097/00000421-200006000-00019 · DOI
  14. Shoji, 2014, A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study), Cancer Chemother. Pharmacol., 73, 895, 10.1007/s00280-014-2418-8 · DOI
  15. Smith, 2006, Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906, Leuk. Lymphoma, 47, 1511, 10.1080/10428190600581385 · DOI
  16. Wagner, 2008, Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors, J. Neurooncol, 86, 175, 10.1007/s11060-007-9444-x · DOI
  17. Xenidis, 2011, Alpha multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer, Cancer Chemother. Pharmacol., 68, 63, 10.1007/s00280-010-1427-5 · DOI
  18. Sugimoto, 1990, Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines, Cancer Res., 50, 7962
  19. Oguro, 1990, Collateral drug sensitivity induced in CPT-11 (a novel derivative of camptothecin)-resistant cell lines, Biomed. Pharmacother., 44, 209, 10.1016/0753-3322(90)90026-6 · DOI
  20. Krauze, 2007, Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts, Neuro Oncol., 9, 393, 10.1215/15228517-2007-019 · DOI
  21. Shaikh, 2013, Liposome co-encapsulation of synergistic combination of irinotecan and doxorubicin for the treatment of intraperitoneally grown ovarian tumor xenograft, J. Control. Release, 172, 852, 10.1016/j.jconrel.2013.10.025 · DOI
  22. Hanada, 2007, Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo, Cancer Sci., 98, 447, 10.1111/j.1349-7006.2007.00404.x · DOI
  23. Takigawa, 2006, The combination effect of amrubicin with cisplatin or irinotecan for small-cell lung cancer cells, Oncol. Rep., 15, 837
  24. Barua, 2013, Synergistic targeting of cell membrane, cytoplasm, and nucleus of cancer cells using rod-shaped nanoparticles, ACS Nano, 7, 9558, 10.1021/nn403913k · DOI
  25. Grant, 1992, Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients, J. Clin. Oncol., 10, 484, 10.1200/JCO.1992.10.3.484 · DOI
  26. Lammers, 2005, Effect of physicochemical modification on the biodistribution and tumor accumulation of HPMA copolymers, J. Control. Release, 110, 103, 10.1016/j.jconrel.2005.09.010 · DOI
  27. Sadekar, 2011, Comparative biodistribution of PAMAM dendrimers and HPMA copolymers in ovarian-tumor-bearing mice, Biomacromolecules, 12, 88, 10.1021/bm101046d · DOI
  28. Tabata, 1998, Tumor accumulation of poly(vinyl alcohol) of different sizes after intravenous injection, J. Control. Release, 50, 123, 10.1016/S0168-3659(97)00129-6 · DOI
  29. Kopecek, 2001, Water soluble polymers in tumor targeted delivery, J. Control. Release, 74, 147, 10.1016/S0168-3659(01)00330-3 · DOI
  30. Duncan, 2009, Development of HPMA copolymer–anticancer conjugates: clinical experience and lessons learnt, Adv. Drug Deliv. Rev., 61, 1131, 10.1016/j.addr.2009.05.007 · DOI
  31. Vasey, 1999, Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents–drug–polymer conjugates. Cancer Research Campaign Phase I/II Committee, Clin. Cancer Res., 5, 83
  32. Tardi, 2009, In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy, Leuk. Res., 33, 129, 10.1016/j.leukres.2008.06.028 · DOI
  33. Mayer, 2006, Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice, Mol. Cancer Ther., 5, 1854, 10.1158/1535-7163.MCT-06-0118 · DOI
  34. Platt, 2008, Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor, Mol. Pharm., 5, 474, 10.1021/mp800024g · DOI
  35. Journo-Gershfeld, 2012, Hyaluronan oligomers–HPMA copolymer conjugates for targeting paclitaxel to CD44-overexpressing ovarian carcinoma, Pharm. Res., 29, 1121, 10.1007/s11095-012-0672-1 · DOI
  36. Choi, 2010, Self-assembled hyaluronic acid nanoparticles for active tumor targeting, Biomaterials, 31, 106, 10.1016/j.biomaterials.2009.09.030 · DOI
  37. Chou, 2006, Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies, Pharmacol. Rev., 58, 621, 10.1124/pr.58.3.10 · DOI · Paper page
  38. Lee, 2008, Hyaluronic acid–paclitaxel conjugate micelles: synthesis, characterization, and antitumor activity, Bioconjug. Chem., 19, 1319, 10.1021/bc8000485 · DOI
  39. Minko, 2000, Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma, Int. J. Cancer, 86, 108, 10.1002/(SICI)1097-0215(20000401)86:1<108::AID-IJC17>3.0.CO;2-8 · DOI
  40. Walton, 1993, Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis, Cancer Res., 53, 1853
  41. Wang, 2004, Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. Intermediacy of H(2)O(2)- and p53-dependent pathways, J. Biol. Chem., 279, 25535, 10.1074/jbc.M400944200 · DOI
  42. Pulaski, 2001, Mouse 4T1 breast tumor model, Curr. Protoc. Immunol., 10.1002/0471142735.im2002s39 · DOI · Paper page
  43. Fantozzi, 2006, Mouse models of breast cancer metastasis, Breast Cancer Res., 8, 212, 10.1186/bcr1530 · DOI
  44. Pavillard, 2001, Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants, Br. J. Cancer, 85, 1077, 10.1054/bjoc.2001.2027 · DOI
  45. Budman, 2002, In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines, Breast Cancer Res. Treat., 74, 41, 10.1023/A:1016070230538 · DOI
  46. Budman, 2006, Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents, Oncology, 70, 147, 10.1159/000093006 · DOI
  47. Budman, 1998, In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents, Anticancer Drugs, 9, 697, 10.1097/00001813-199809000-00005 · DOI
  48. Liu, 2014, Codelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activity, Mol. Pharm., 11, 1651, 10.1021/mp5000373 · DOI
  49. Clements, 1996, Camptothecin exhibits selective cytotoxicity towards human breast carcinoma as compared to normal bovine endothelial cells in vitro, Anticancer Drugs, 7, 851, 10.1097/00001813-199611000-00006 · DOI
  50. Jones, 1997, Sensitivity to camptothecin of human breast carcinoma and normal endothelial cells, Cancer Chemother. Pharmacol., 40, 475, 10.1007/s002800050690 · DOI
  51. Gottlieb, 1970, Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880), Cancer Chemother. Rep., 54, 461
  52. Gabizon, 1994, Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene–glycol coated liposomes, Cancer Res., 54, 987
  53. Luo, 2001, Hyaluronic acid-N-hydroxysuccinimide: a useful intermediate for bioconjugation, Bioconjug. Chem., 12, 1085, 10.1021/bc015513p · DOI
  54. Dvorak, 1999, High-molecular weight HPMA copolymer–adriamycin conjugates, J. Control. Release, 60, 321, 10.1016/S0168-3659(99)00087-5 · DOI
  55. Lammers, 2009, Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers, Biomaterials, 30, 3466, 10.1016/j.biomaterials.2009.02.040 · DOI
  56. Shiah, 1999, Biodistribution of free and N-(2-hydroxypropyl)methacrylamide copolymer-bound mesochlorin e(6) and adriamycin in nude mice bearing human ovarian carcinoma OVCAR-3 xenografts, J. Control. Release, 61, 145, 10.1016/S0168-3659(99)00113-3 · DOI
  57. Amaravadi, 2007, The roles of therapy-induced autophagy and necrosis in cancer treatment, Clin. Cancer Res., 13, 7271, 10.1158/1078-0432.CCR-07-1595 · DOI
  58. Kiaris, 1999, Apoptosis versus necrosis: which should be the aim of cancer therapy?, Exp. Biol. Med., 221, 87, 10.3181/00379727-221-44388 · DOI
  59. Ottewell, 2008, Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer, J. Natl. Cancer Inst., 100, 1167, 10.1093/jnci/djn240 · DOI
  60. Chen, 2010, Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer, J. Biol. Chem., 285, 22639, 10.1074/jbc.M110.125906 · DOI
  61. Watanabe, 2008, In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin, J. Control. Release, 127, 231, 10.1016/j.jconrel.2008.02.005 · DOI
  62. Bourguignon, 2008, Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression, Semin. Cancer Biol., 18, 251, 10.1016/j.semcancer.2008.03.007 · DOI
  63. Mero, 2014, Hyaluronic acid bioconjugates for the delivery of bioactive molecules, Polymers, 6, 346, 10.3390/polym6020346 · DOI
  64. Mackay, 1994, Expression and modulation of CD44 variant isoforms in humans, J. Cell Biol., 124, 71, 10.1083/jcb.124.1.71 · DOI
  65. Hellstrom, 2006, Hyaluronan and its receptor CD44 in the heart of newborn and adult rats, Anat. Rec. A Discov. Mol. Cell. Evol. Biol., 288, 587, 10.1002/ar.a.20332 · DOI

Cited by

Sorted by citations

Metadata

Authors
Camacho, K. M., Kumar, S., Menegatti, S., Vogus, D. R., Anselmo, A. C., & Mitragotri, S.
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2015-07
Volume
210
Pages
198-207
ISSN
0168-3659
DOI
10.1016/j.jconrel.2015.04.031
PMC
PMC4470752
Cited by
97
References
0
Language
en
Licence
Funders
  • NIH (1S10 OD010610-01A1)
  • University of California, Santa Barbara
  • University of California, Office of the President
  • NSF (DGE-1144085)
  • UCSB's Center for Bioengineering

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review